Skip to content
Peptide research

GHRP-6

Also known as Growth Hormone Releasing Peptide 6 · SKF-110679
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic six-amino-acid peptide that spikes growth hormone via the ghrelin receptor, marketed for muscle gain, recovery, and appetite. Higher GH and IGF-1 are its dependable effects, while claims of heart and organ protection rest only on animal and mechanism data. It drives the strongest hunger of any GHRP, can raise cortisol and blood sugar, with no long-term human safety data. Not FDA-approved; unregulated products sold online vary in purity.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic 6-amino-acid peptide and one of the earliest compounds developed to stimulate growth hormone release. Created by researcher Cyril Bowers, it was the first synthetic peptide proven to specifically trigger growth hormone production both in lab settings and in living organisms. GHRP-6 works by mimicking ghrelin, the body's hunger hormone, and has a half-life of about 2.5 hours. It requires injection, as oral absorption is less than 1%.

How it works in the body

Activates the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells, triggering a calcium-mediated burst of growth hormone release. It simultaneously stimulates ghrelin pathways in the hypothalamus, which strongly increases appetite and gastric motility alongside GH elevation.

Research overview

GHRP-6 has been studied since the early 1990s both as a growth hormone booster and a tissue-protective agent. It requires your body's own growth hormone-releasing hormone (GHRH) to work at full strength — blocking GHRH reduces its effect by roughly 80%. Beyond growth hormone, GHRP-6 activates a separate receptor (CD36) that triggers cell survival pathways, which explains its documented heart-protective, liver-protective, kidney-protective, and gut-protective effects in animal studies. It is the most appetite-stimulating peptide in its class due to strong activation of the ghrelin receptor. Human studies are limited primarily to short-term growth hormone stimulation tests and pharmacology studies. Despite a broad preclinical safety profile, clinical development has been inconsistent: GHRP-6 combined with EGF has reached a Phase III stroke trial, which missed its primary endpoint, and efficacy of GHRP-6 alone remains unestablished.

Who researches GHRP-6?

Commonly researched by

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

Important considerations for

  • Those with Active cancer

    High

    GH secretagogue — promotes tumor growth via GH/IGF-1.

  • Those with Eating disorders

    High

    GHRP-6 causes intense hunger through ghrelin activation. Problematic for binge eating.

  • Those with Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen retinal neovascularization.

  • Those with Diabetes/insulin resistance

    Moderate

    GH elevation can worsen blood sugar control and insulin sensitivity.

Safety & interactions

Do not use if

  • Active cancer

    High

    GH secretagogue — promotes tumor growth via GH/IGF-1.

  • Eating disorders

    High

    GHRP-6 causes intense hunger through ghrelin activation. Problematic for binge eating.

  • Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen retinal neovascularization.

  • Diabetes/insulin resistance

    Moderate

    GH elevation can worsen blood sugar control and insulin sensitivity.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Intense appetite stimulation (strongest among GHRPs)

    High

    Shared GHS-R1a mechanism with ghrelin, Wren et al. 2001, PMID 11739476 (analog evidence); GHRP-6 characterized as most appetite-inducing GHRP

  • Cortisol and ACTH elevation (non-selective GHS-R activation)

    Moderate

    Frieboes et al. 1995, PMID 7617137 (human — title reports ACTH and cortisol release in normal man); ghrelin vs GHRP-6 in Cushing's, PMID 16832586

  • Prolactin elevation; potential gynecomastia with chronic use

    Low

    Prolactin rise with GHRP-6/hexarelin in humans, Frieboes et al. 1995, PMID 7617137; gynecomastia inferred, not demonstrated

  • Water retention and joint discomfort from GH/IGF-1

    Low

    Established rhGH/IGF-1 therapy adverse-effect profile (extrapolated); GHRP-6-specific incidence not trialed

  • Blood glucose effects; potential insulin resistance

    Moderate

    Ghrelin/GHS-R glucose-insulin homeostasis review, PMC2911604; insulin/glucose-status-dependent effects, PMID 20219977 (animal); GH counter-regulatory physiology

  • No long-term human safety data

    High

    No long-term RCTs on ClinicalTrials.gov; human data limited to acute studies (PMID 7617137) and small retrospective series (PMID 28830317)

Interaction summary(6)

Rated by direction with this peptide

  • GHRH analogs (sermorelin, CJC-1295, tesamorelin)

    SynergisticModerate

    GHRP-6 (a GHS-R1a agonist) and GHRH act through distinct, complementary pituitary pathways, and their combination produces a markedly greater, supra-additive GH pulse than either alone in humans. This is the classic, intentionally exploited GHRP+GHRH synergy; the caution is amplified GH/IGF-1 exposure and downstream fluid/glucose effects.

    Classic human GHRP+GHRH synergy endocrinology (Bowers); GHS-R1a vs GHRH-R distinct-pathway mechanism

  • Somatostatin analogs (octreotide, lanreotide)

    CautionModerate

    Somatostatin tone directly suppresses pituitary GH release and blunts the GH response to GHRP-6, so co-use pharmacodynamically antagonizes and reduces the peptide's primary effect. Directionally this is loss of efficacy, not added toxicity.

    Somatostatin suppression of secretagogue-stimulated GH; GHRP-6 response modulation, comparison work PMID 16832586

  • Insulin and antidiabetic agents (insulin, sulfonylureas, metformin)

    CautionModerate

    GH released by GHRP-6 is counter-regulatory and can raise glucose and transiently lower peripheral insulin sensitivity, potentially offsetting glycemic control in treated diabetics. Mechanism-based; magnitude is dose- and metabolic-status-dependent, and no human co-administration trials exist.

    GH counter-regulatory physiology; ghrelin/GHS-R glucose homeostasis PMC2911604; insulin-status-dependent effects PMID 20219977 (animal)

  • Doxorubicin / anthracycline chemotherapy

    ProtectiveTheoretical

    In rats, concurrent GHRP-6 markedly reduced anthracycline cardiotoxicity and multi-organ (liver/kidney/lung) damage via antioxidant and anti-apoptotic (Bcl-2) mechanisms. This is a protective, not harmful, interaction, but it is entirely preclinical; there are no human data and any tumor-context effects are unstudied.

    Doxorubicin cardio/cytoprotection, Front Pharmacol 2024, PMC11169835 (animal)

  • Glucocorticoids / corticosteroids (prednisone, dexamethasone)

    CautionLow

    GHRP-6 itself activates the HPA axis (raising ACTH and cortisol), so layering exogenous glucocorticoids is additive on cortisol-related effects; chronic steroid exposure also blunts the GH response to secretagogues. Interaction is mechanism-based with no dedicated human co-administration studies.

    GHRP-6 ACTH/cortisol elevation in man, Frieboes et al. 1995, PMID 7617137; glucocorticoid modulation of GH secretagogue response

  • Other GHS-R1a agonists / ghrelin mimetics (GHRP-2, hexarelin, ipamorelin, MK-677/ibutamoren)

    CautionTheoretical

    These act on the same GHS-R1a receptor, so using them together is largely redundant: little additional GH benefit once the receptor is maximally engaged, while shared side effects (appetite, and for the non-selective ones cortisol/prolactin) are additive. Theoretical, based on common receptor pharmacology.

    Shared GHS-R1a mechanism; GHRP receptor-saturation pharmacology

Known risks(9)

  • Intense appetite stimulation (hunger) — strongest among GHRPs, may be problematic for weight management

  • Cortisol and ACTH elevation — non-selective GHS-R activation increases stress hormones unlike Ipamorelin

  • Prolactin elevation — potential for gynecomastia with chronic use

  • Water retention and potential joint discomfort from GH/IGF-1 elevation

  • Blood glucose effects — carbohydrate/fat blunts GH response; potential insulin resistance with chronic use

  • No long-term human safety data — clinical studies limited to acute/short-term administration

  • Not FDA-approved — no manufacturing quality standards; research chemical purity varies

  • Theoretical cancer risk with prolonged GH/IGF-1 axis stimulation

  • Tachyphylaxis possible with continuous (non-pulsatile) administration

Drug interactions(6)

  • CJC-1295 / GHRH analogs

    GHRP-6 + GHRH produces striking synergistic GH release. AUC dramatically exceeds either alone. Most common clinical pairing for GH optimization.

  • Ipamorelin

    Both are GHS-R agonists. Ipamorelin has a cleaner profile (no cortisol/prolactin effects).

  • GHRP-2

    GHRP-2 is more potent for GH release with less appetite stimulation. Both act on the same receptor target.

  • Insulin

    Simultaneous insulin administration increases GH response to GHRP-6. However, chronic GH elevation may impair insulin sensitivity.

  • Metoprolol (beta-blocker)

    No pharmacological interaction documented between GHRP-6 and metoprolol in clinical studies.

  • Carbohydrates / dietary fat

    Recent carbohydrate and fat intake significantly blunts GH release from GHRP-6. Best administered fasting.

Research & benefits

Evidence base

Evidence Level
Mostly Preclinical
Total Studies
60
Human Studies
8

Extensive preclinical evidence for GH secretion, cardioprotection, and cytoprotection across multiple organ systems. Human studies limited to GH-stimulation tests (healthy volunteers and children with short stature), diagnostic use for pituitary reserve evaluation, and comparative studies in Cushing's disease. Oral GHRP-6 (300 mcg/kg) shown effective in children. A Phase III trial of GHRP-6 combined with EGF in 188 stroke patients missed its primary endpoint. This does not establish efficacy of GHRP-6 alone; cardiac and multi-organ protection remain preclinical.

Researched for(7)

Rated by confidence in the evidence

  • Potent GH release

    High

    Human crossover trials confirm strong GH release, exceeding GHRH alone and synergistic when combined.

    Frieboes et al. 1995, Neuroendocrinology 61(5):584-589, PMID 7617137 (human crossover; abstract reports 15.4±9.6 vs 5.5±4.0 ng/mL); mechanism GHS-R1a on pituitary somatotrophs

  • Cardioprotection

    Low

    Animal studies in rats, pigs, and dogs show protection against heart damage; no human trials yet.

    Doxorubicin cardiotoxicity rat study, Front Pharmacol 2024, PMC11169835 (animal); post-MI remodeling, Pharmaceuticals (MDPI) 2026, mdpi.com/1424-8247/19/3/468 (animal/rat)

  • Cytoprotection (multi-organ)

    Low

    Rat ischemia-reperfusion models show liver, kidney, lung, and gut protection; no human data.

    Front Pharmacol 2024, PMC11169835 (Wistar rats); GHS-R/CD36 pro-survival mechanism

  • Appetite stimulation

    Medium

    Human trials show ghrelin raises appetite via the same receptor; direct GHRP-6 data is limited.

    Ghrelin appetite in humans, Wren et al. 2001 J Clin Endocrinol Metab 86(12):5992, PMID 11739476 (randomized double-blind crossover — ghrelin evidence, not GHRP-6-direct); shared GHS-R1a mechanism

  • IGF-1 elevation

    Medium

    A small retrospective study found higher IGF-1 during combined GHRP-6, GHRP-2 and sermorelin treatment. It did not establish muscle or tissue-repair benefits from GHRP-6 alone.

    Sigalos et al. 2017, Am J Mens Health 11(6):1752-1757, PMID 28830317 / PMC5675260 (human retrospective; baseline IGF-1 159.5 ng/mL, n=14 compliant, GHRP-6+GHRP-2+SERM); aged-rat dissociation, PMID 10407366

  • Anti-fibrotic activity

    Low

    Animal models of cardiac and liver fibrosis show reduced fibrosis markers; no human data.

    Front Pharmacol 2024, PMC11169835 (animal)

  • Anti-inflammatory

    Low

    Animal studies show lower inflammatory cytokines and oxidative stress; human evidence is lacking.

    Antioxidant/anti-apoptotic mechanism, Front Pharmacol 2024, PMC11169835 (animal); GHS-R/CD36 anti-inflammatory reviews

Benefits(7)

  • Potent GH release

  • Cardioprotection

  • Cytoprotection (multi-organ)

  • Appetite stimulation

  • IGF-1 elevation

  • Anti-fibrotic activity

  • Anti-inflammatory

Key studies(7)

  1. Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA

    J Clin Endocrinol Metab

    1998

    GHRH antagonist reduced GHRP-6 peak GH from 33.8 to 6.2 mcg/L and AUC from 1701 to 376 mcg*min/L. Endogenous GHRH necessary for ~80% of GH response.

  2. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF

    J Clin Endocrinol Metab

    1995

    Complete blockade of GHRP-6 GH response in hypothalamopituitary disconnection patients (97.3 vs 1434.8 mcg/L in controls). Proves primary hypothalamic site of action.

  3. Bellone J, Ghizzoni L, Aimaretti G, Volta C, Boghen MF, Bernasconi S, Ghigo E

    Eur J Endocrinol

    1995

    Oral GHRP-6 (300 mcg/kg) produced GH peak of 18.8 mcg/L in children, comparable to IV GHRH. Combined with arginine further enhanced response.

  4. Correa-Silva SR, Nascif SO, Lengyel AM

    Pituitary

    2006

    GHRP-6 GH peak 2.7 mcg/L in Cushing's vs normal, enhanced ACTH response. Demonstrates deranged GHS-R pathways in chronic hypercortisolism.

  5. Berlanga-Acosta J et al.

    Front Pharmacol

    2024

    GHRP-6 (400 mcg/kg BID) prevented ventricular dilation, preserved LVEF, reduced morbidity/mortality, and attenuated multi-organ damage from doxorubicin via GHSR1a/CD36 dual activation.

  6. Berlanga-Acosta J et al.

    Clinical Medicine Insights: Cardiology

    2017

    Comprehensive review of GHRP cytoprotection: cardioprotection, hepatoprotection, renal/pulmonary/GI protection via GHS-R1a and CD36 signaling. Broad safety profile but no established clinical niche.

  7. Popovic V, Micic D, Damjanovic S, et al.

    Journal of Pediatric Endocrinology and Metabolism

    1996

    GHRP-6 evaluated as diagnostic tool for assessing pituitary GH reserve. Reliable and reproducible GH stimulation test.

Regulation & availability

Why researchers look at it

The first synthetic peptide ever proven to trigger growth hormone release in living organisms, with compelling animal data showing heart, liver, kidney, and gut protection through a separate receptor (CD36) unrelated to GH. Its powerful appetite stimulation — the strongest in its class — has drawn clinical interest for patients who need to gain weight. GHRP-6 combined with EGF has been tested for neuroprotection in human stroke trials, but these do not establish benefit from GHRP-6 alone. It is not FDA-approved and is listed in 503A Category 3 and 503B Category 2.

Estimated cost
No approved product and no verified reference price
FDA status
Not FDA-approved. GHRP-6 is in 503A Category 3 (FDA found its nomination for the compounding list lacked adequate support) and 503B Category 2. FDA dates the 503B safety placement to September 29, 2023, citing immunogenicity and impurity concerns, limited safety information, cortisol effects and potential increases in blood glucose from reduced insulin sensitivity. No ATC code assigned.
WADA status
Prohibited at all times (in- and out-of-competition). Listed under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics — specifically as a GH-releasing peptide (GHRP). On the 2026 WADA Prohibited List effective January 1, 2026.
Prescribability
GHRP-6 is not FDA-approved and is not eligible for compounding: FDA found that its nomination for the compounding list lacked adequate support (Category 3), and it lists GHRP-6 as a safety risk for outsourcing facilities (503B Category 2).
Availability
Not FDA-approved for any indication. GHRP-6 is in 503A Category 3 and 503B Category 2 and is not covered by Category 1 interim enforcement discretion for bulk compounding. FDA's stated concerns include immunogenicity, peptide impurities, cortisol effects and reduced insulin sensitivity. No USP monograph. Oral bioavailability <1% necessitates injectable (subcutaneous or IV) administration. Unregulated products sold online carry no quality assurance or regulatory oversight.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(10)

  1. 1984
    DiscoveryCyril Bowers discovers met-enkephalin analogs with GH-releasing activity, leading to GHRP-6 development.
  2. 1995
    Key clinical studiesPopovic et al. demonstrate hypothalamic site of action. Bellone et al. show oral efficacy in children.
  3. 1996
    GHS-R identifiedGrowth hormone secretagogue receptor (GHS-R1a) identified, later found to be the ghrelin receptor.
  4. 1998
    GHRH dependency provenPandya et al. demonstrate GHRP-6 requires endogenous GHRH for ~80% of GH response.
  5. 1999
    Ghrelin discoveredKojima et al. discover ghrelin as the endogenous ligand of GHS-R1a, validating GHRP-6's mechanism.
  6. 2004+
    WADA prohibitionGH-releasing peptides including GHRP-6 added to WADA Prohibited List under S2 category.
  7. 2017
    Cytoprotection reviewBerlanga-Acosta et al. publish comprehensive review of GHRP cytoprotective evidence (PMC5392015).
  8. 2023-09-29
    FDA 503B Category 2FDA places GHRP-6 in 503B Category 2 because of significant safety concerns. Its 503A placement is Category 3.
  9. 2024
    Cardioprotection studyBerlanga-Acosta et al. publish GHRP-6 doxorubicin cardioprotection data in Frontiers in Pharmacology.
  10. 2026-01
    WADA 2026 ListGHRP-6 remains prohibited under 2026 WADA Prohibited List (effective Jan 1, 2026).

Sources & FAQs

Research sources(10)

Frequently asked questions(6)

What is GHRP-6 and how does it work?

GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that stimulates growth hormone release by binding to the ghrelin receptor (GHS-R1a) at the hypothalamic and pituitary level. It also binds CD36 scavenger receptors, activating cytoprotective signaling. It requires endogenous GHRH for maximal GH response.

How does GHRP-6 differ from GHRP-2 and Ipamorelin?

GHRP-6 is the strongest appetite stimulator of the three due to potent ghrelin mimicry. Unlike Ipamorelin (which is selective for GH only), GHRP-6 also increases ACTH, cortisol, and prolactin. GHRP-2 is intermediate — more potent GH release than GHRP-6 but less appetite stimulation.

Is GHRP-6 legal to use?

GHRP-6 is not FDA-approved. For US bulk compounding, it is in 503A Category 3 and 503B Category 2, without Category 1 interim enforcement discretion. It is banned by WADA for athletes.

What are the main side effects of GHRP-6?

The most notable side effect is intense appetite stimulation (hunger) shortly after injection. Other reported effects include water retention, transient cortisol/prolactin elevation, potential blood sugar effects, and injection site reactions. Long-term safety data in humans is lacking.

Can GHRP-6 be taken orally?

Oral bioavailability is less than 1%, making oral administration impractical for systemic GH effects. However, one clinical study showed high oral doses of GHRP-6 produced measurable GH release in children.

What is GHRP-6's role in cardioprotection?

Preclinical studies show GHRP-6 protects the heart through CD36 receptor activation, engaging PI-3K/AKT1 survival pathways, reducing apoptosis, fibrosis, and oxidative stress. It prevented doxorubicin cardiomyopathy in rats and achieved 100% survival in canine dilated cardiomyopathy models.